Journal of Medical Imaging and Radiation Oncology最新文献

{"title":"Interpreting Embolic Agent Comparisons in Renal Angiomyolipoma Embolisation","authors":"Daniel Westby, Michael G. Curran, Brian M. Moloney","doi":"10.1111/1754-9485.70129","DOIUrl":"10.1111/1754-9485.70129","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"429-430"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Australian MRI Linac Program: From Pie in the Sky to Research Milestone","authors":"Michael Bernard Barton,&nbsp;Geoffrey Paul Delaney,&nbsp;Peter Greer,&nbsp;Lois Holloway,&nbsp;Peter Metcalfe,&nbsp;Robba Rai,&nbsp;Trang Pham,&nbsp;William S. Price,&nbsp;David Waddington,&nbsp;Stuart Crozier,&nbsp;Paul Keall","doi":"10.1111/1754-9485.70133","DOIUrl":"10.1111/1754-9485.70133","url":null,"abstract":"<p>The Australian Magnetic Resonance Imaging (MRI) Linear Accelerator program (MRI linac) was a major research project that aimed to build and test a unique MRI linac prototype for cancer treatment. It aimed to improve radiotherapy anatomical targeting and explore physiological targeting. The purpose of this report is to summarise the development and achievements of the program so as to provide an example of a successful large-scale research project in Australian radiation oncology. The project involved six Australian universities and international collaborators. We developed and built a unique MRI linac configuration comprising a 1 T magnetic field and a 6 MV accelerator, with the beam delivered in line with B₀ and the patient placed across B₀ in the split between the two halves of the magnet. The broad research domains were personalised disease targeting, medical device innovation, and biodiscovery. Specific projects included Artificial Intelligence image enhancement, radiation dosimetry in high magnetic fields, MRI characterisation of cancer heterogeneity in human tumours, and animal and human studies. Over $27 million was obtained to support the program from competitive sources. The program published over 120 papers and supported 25 PhD completions. The learnings from the Australian MRI linac program are that Australia has world-class radiotherapy research in physics and engineering, that major projects need a lot of time and a lot of collaboration, and that large, novel radiotherapy projects can attract significant funding and produce significant results.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"70 5","pages":"477-486"},"PeriodicalIF":1.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.70133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and Medium-Term Efficacy of Super-Selective Haemorrhoidal Artery Embolisation for Internal Haemorrhoids and Its Relationship With Severity Grading: A Single-Centre Retrospective Study.","authors":"Hengrui Cai, Hao Zhang, Ruochong Pang, Mingqing Zhang, Wenwen Wang, Liang Yin, Jian Zhang, Jian Jing, Xingwei Sun, Yong Jin","doi":"10.1111/1754-9485.70165","DOIUrl":"https://doi.org/10.1111/1754-9485.70165","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the 12-month symptom relief rate of super-selective haemorrhoidal artery embolisation (HAE) for Grade I-IV internal haemorrhoids and analyse the impact of haemorrhoid grading and embolisation site on treatment efficacy.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 32 patients with internal haemorrhoids who underwent HAE at the Interventional Radiology Department of The Second Affiliated Hospital of Soochow University between April 2020 and January 2025. Efficacy was assessed using Visual Analogue Scale (VAS) and French Bleeding Scale (FBS) scores at 1, 3, 6, and 12 months postoperatively.</p><p><strong>Results: </strong>The clinical success rate at 1 month post-procedure (defined as clinical success: ≥ 50% reduction in VAS or FBS from baseline without requiring any reintervention during follow-up) was 87.5% (28/32). The rates at 3 months, 6 months, and 12 months were 68.8% (22/32), 59.4% (19/32), and 56.2% (18/32). The VAS score decreased from 4.25 ± 1.08 preoperatively to 3.53 ± 1.39 at 1 month postoperatively (p < 0.001), rising to 3.72 ± 1.46 at 12 months postoperatively (p < 0.001). The FBS score decreased from 6.09 ± 1.84 preoperatively to 2.06 ± 1.41 at 1 month postoperatively (p < 0.001), and rebounded to 3.84 ± 2.10 at 12 months postoperatively (p < 0.001). The 12-month efficacy rate remained at 100% for Grade I haemorrhoids, 54.5% for Grade II, 50% for Grade III, and 40% for Grade IV. Minor complications occurred in 9.4% of patients, all resolving without intervention.</p><p><strong>Conclusion: </strong>HAE demonstrates reliable short-term efficacy for bleeding from Grade I-III internal haemorrhoids. As follow-up duration increases and severity grades rise, symptom relief rates gradually decline. The procedure is safe and reproducible, serving as an alternative minimally invasive option for patients unwilling or unable to undergo excision for Grade I-III internal haemorrhoids. However, patients should be informed of the recurrence risk, and long-term efficacy requires further investigation.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition Zone Prostate Cancer: Quantitative Synthetic MR Imaging and Diffusion-Weighted Imaging in Tumour Detection.","authors":"Yu Zhang, Feng Li, Lei Song, Yanlong Jia, Zhihao Li, Shijun Jia","doi":"10.1111/1754-9485.70155","DOIUrl":"https://doi.org/10.1111/1754-9485.70155","url":null,"abstract":"<p><strong>Background: </strong>Differentiating transition zone (TZ) prostate cancer (PCa) from benign prostatic hyperplasia (BPH) on multiparametric MRI is challenging. The comparative performance of synthetic MRI (Sy-MRI) and apparent diffusion coefficient (ADC) for this task is unclear.</p><p><strong>Purpose: </strong>To evaluate the utility of Sy-MRI parameters and ADC in distinguishing TZ PCa from BPH.</p><p><strong>Materials and methods: </strong>This retrospective study included 261 patients (89 PCa, 172 BPH) who underwent preoperative MRI (including DWI and Sy-MRI). Two independent radiologists, who did not have access to the histopathological diagnosis and clinical data, placed regions of interest (ROIs) by manually tracing the lesion margins at the largest cross-sectional area of the lesion on the ADC map to record the ADC values. On synthetic T1-mapping, T2-mapping and proton density (PD) maps, ROIs of comparable size were placed at the same level and in a corresponding location to record T1, T2 and PD values. Parameters were compared using the t-test or Mann-Whitney U test. Diagnostic performance was assessed with ROC analysis and the DeLong test.</p><p><strong>Results: </strong>T1, T2 and ADC values were significantly lower in PCa than in BPH (all p ≤ 0.001), while PD showed no difference (p = 0.073). ADC yielded the highest diagnostic performance (AUC, 0.996 [95% CI: 0.992, 1]), which was significantly higher than that of T1 (AUC, 0.928 [95% CI: 0.893, 0.964]) and T2 (AUC, 0.907 [95% CI: 0.868, 0.947]) (both p < 0.001).</p><p><strong>Conclusion: </strong>Sy-MRI-derived T1 and T2 values can help differentiate PCa from BPH in the TZ; however, ADC remains the superior diagnostic performance within this enriched cohort of predominantly intermediate- to high-risk tumours.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOAR Study: Southern Outcomes in Aortic Rule-Out (ADvISED External Validation Study).","authors":"Matt Beaumont, Chirag Udhani, Ben Wilson","doi":"10.1111/1754-9485.70154","DOIUrl":"https://doi.org/10.1111/1754-9485.70154","url":null,"abstract":"<p><strong>Background: </strong>Acute aortic syndromes (AAS), including aortic dissection, intramural haematoma (IMH), and penetrating atherosclerotic ulcer (PAU), are uncommon but life-threatening causes of chest pain. Computed tomography angiography (CTA) is highly sensitive for AAS but is increasingly overutilised despite low diagnostic yield, exposing patients to radiation, contrast risk, and healthcare cost. The ADvISED rule-out algorithm, combining the Aortic Dissection Detection Risk Score (ADD-RS) with serum D-dimer, has demonstrated high negative predictive value (NPV) in prospective studies but has limited external validation.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of adult emergency department patients within a tertiary cardiothoracic referral network in southern New Zealand who underwent CTA for suspected AAS between January 2018 and January 2024. Clinical records were reviewed to retrospectively calculate ADD-RS and extract D-dimer results prior to imaging. CTA findings served as the reference standard. The primary outcome was the NPV and failure rate of the ADvISED rule-out algorithm (low ADD-RS [0-1] plus negative D-dimer < 500 ng/mL).</p><p><strong>Results: </strong>Of 1392 CTA studies reviewed, 1000 met inclusion criteria. Forty-one patients (4.1%) were diagnosed with AAS. Among patients with low ADD-RS and negative D-dimer (n = 180), one case of AAS (IMH) was identified, yielding an NPV of 99.4% and a failure rate of 0.6%. No Stanford type A AAS were missed. Most non-AAS diagnoses were non-specific chest pain (45%) or cardiac conditions (20%), with fewer than 1% benefiting from alternative angiographic diagnoses.</p><p><strong>Conclusions: </strong>In this regional emergency department cohort, the ADvISED rule-out algorithm demonstrated excellent negative predictive value and safely excluded AAS in low-risk patients. External validation in this population supports its use as a clinical decision aid to reduce unnecessary CTA utilisation without compromising patient safety. Prospective implementation studies are warranted to further assess its impact on imaging stewardship and clinical outcomes.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional Radiology Society of Australasia Quality Care Guidelines for Renal Tumour Ablation in Australia and New Zealand.","authors":"Matthew Lukies, William Ormiston, Nicholas Brown, Philip Chan, Ahmad Al-Hindawi, Radha Popuri, Brendan Buckley","doi":"10.1111/1754-9485.70148","DOIUrl":"https://doi.org/10.1111/1754-9485.70148","url":null,"abstract":"<p><p>Image-guided thermal ablation (radiofrequency, cryo- and microwave ablation) is a safe and effective primary treatment for small renal mass and localised renal cell carcinoma ≤ 4 cm (T1a) with long-term cancer-specific survival rates equivalent to surgical resection (Level A). Image-guided thermal ablation can be considered as a treatment option for localised renal cell carcinoma > 4 cm (T1b) (Level B). Image-guided thermal ablation is a nephron-sparing treatment option, particularly for renal cell carcinoma in the solitary or syndromic kidney (Level B). Patients referred for consideration of image-guided thermal ablation of a small renal mass or RCC should be consulted pre-operatively by an Interventional Radiologist (IR) including comprehensive clinical evaluation and assessment of suitability (Level C). Pre-operative work-up should include medical history, physical examination, evaluation of functional status, comorbidities, assessment of coagulation status and renal function, and review of relevant imaging (Level B). Renal mass biopsy is recommended either prior to or at the time of image-guided thermal ablation (Level B). Tumour embolisation prior to thermal ablation is not routinely recommended (Level B). Renal tumour ablation should be performed with general anaesthetic or deep sedation, under cross-sectional imaging, and achieve an ablation zone margin of 5-10 mm. Adjunctive techniques should be used if the tumour is close to thermally sensitive structures (Level C). The treating interventional radiologist is a primary clinician responsible for care during a patient's admission for renal tumour ablation, including management of complications (Level C). Follow up after renal tumour ablation should include clinical consultation, renal function assessment, and cross-sectional imaging within 6 months, followed by regular cross-sectional imaging for 5 years (Level C). Renal tumour ablation is a cost-effective and preferred treatment for T1a renal cell carcinoma to maximise health benefits per dollar (Level B). Interventional Radiologists are the medical specialist group with suitable training and expertise to perform image-guided renal tumour ablation in Australia and New Zealand (Level C).</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vertebral Bone Mineral Density Measured on Coronary CT Angiography as a Marker of Coronary Artery Disease Severity.","authors":"Osman Konukoglu, Murat Kaya, Candan Gungor, Baris Can Arslan","doi":"10.1111/1754-9485.70157","DOIUrl":"https://doi.org/10.1111/1754-9485.70157","url":null,"abstract":"<p><strong>Background: </strong>Osteoporosis and atherosclerosis are prevalent diseases that exert significant impacts on morbidity and mortality.</p><p><strong>Purpose: </strong>To investigate the relationship between opportunistically measured thoracic vertebral bone mineral density (BMD) on coronary computed tomography angiography (CCTA) and coronary artery disease (CAD), coronary artery stenosis severity and coronary artery calcium score (CACS).</p><p><strong>Methods: </strong>This retrospective study included 386 patients undergoing CCTA for suspected CAD. BMD was measured on non-contrast images using Hounsfield units (HU), and values < 200 HU were defined as low BMD. Coronary artery stenosis, vessel involvement and CACS were evaluated. Logistic and linear regression analyses were performed to assess associations between BMD, CAD and CACS.</p><p><strong>Results: </strong>Among 386 patients (55.7% male, mean age 51.5 ± 11.4 years), CAD was detected in 49 (12.7%). Low BMD was significantly more frequent in patients with CAD and was independently associated with its presence (OR = 2.98, p = 0.003). The prevalence of coronary artery stenosis was significantly higher in the low BMD group, including LMCA (10.9% vs. 1.9%), LAD (45.0% vs. 20.4%), RCA (27.9% vs. 12.1%) and Cx (20.1% vs. 10.8%) (p < 0.05 for all). Moderate and severe CACS were also more common in patients with low BMD (p < 0.001). BMD showed a significant negative association with CACS.</p><p><strong>Conclusion: </strong>Lower thoracic vertebral BMD is independently associated with the presence and severity of CAD and higher coronary calcium burden. Opportunistic BMD assessment on routine CCTA may serve as a complementary imaging biomarker reflecting overall cardiometabolic risk.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bleomycin and Reversible Electroporation for the Treatment of Vascular Malformations: A New Zealand Tertiary Centre Experience.","authors":"Martin Krauss, Michelle Marais, Missa Mohd Amin","doi":"10.1111/1754-9485.70153","DOIUrl":"https://doi.org/10.1111/1754-9485.70153","url":null,"abstract":"<p><strong>Background: </strong>Vascular malformations (VMs) are congenital anomalies that often cause pain, swelling, disfigurement, and functional impairment. Conventional sclerotherapy, though widely used, typically requires multiple sessions and may yield incomplete resolution. Bleomycin-Electrosclerotherapy (BEST) and Bleomycin-Electroperfusiontherapy (BEPT) combine bleomycin with reversible electroporation to enhance endothelial uptake, potentially improving outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study (January 2024-August 2025) at Christchurch Hospital of 27 patients (40 procedures) with clinically and radiologically confirmed vascular malformations, where bleomycin had been administered percutaneously, intra-arterially or intravenously, followed by electroporation using the IGEA Cliniporator VITAE. Primary outcome was clinical improvement assessed by GAIS. Secondary outcomes included VAS pain scores, number of treatments, complication rates and subgroup analyses. This study is reported in accordance with the STROBE statement for observational studies.</p><p><strong>Results: </strong>The cohort included venous (40.7%), lymphatic (18.5%), venolymphatic (7.4%) and glomovenous malformations (11.1%), intramuscular fast-flow vascular anomaly (3.7%), Klippel-Trenaunay spectrum (3.7%), FAVA (3.7%) and arteriovenous malformations (11.1%). Clinical improvement (GAIS 1-3) was observed in 24/27 patients (88.9%; 95% CI 71.9%-96.1%). Exceptional improvement or resolution (GAIS 1) was achieved in 37.0% and partial improvement (GAIS 2-3) in 51.9%, after a mean of 1.48 sessions. Mean VAS score improved from 6.3 to 2.4 (p < 0.001; Cohen's d = 1.68). Subgroup analysis demonstrated a 100% improvement rate in treatment-naïve patients (n = 7; 95% CI 64.6-100%) and in lymphatic malformations (n = 5; 95% CI 56.6%-100%); both subgroups were small and the wide confidence intervals preclude definitive conclusions. Adverse events included transient sensory nerve loss (18.5%), hyperpigmentation (44.4%) and localised necrosis in intraoral lesions (11.1%), all resolving except for 1 case of permanent hyperpigmentation. No systemic toxicity occurred.</p><p><strong>Conclusion: </strong>BEST and BEPT are effective adjuncts for vascular malformations, reducing treatment burden compared to conventional sclerotherapy and showing particular promise in microcystic lymphatic malformations and selected high-flow AVMs. Larger multicentre studies with extended follow-up are warranted to confirm safety, efficacy, refine patient selection and optimise dosing.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular Treatments for Pulmonary Embolism: A Narrative Historical Review.","authors":"Gary Chen, Julianna Seo, Ariel Dahan, Goran Mitreski, Ali Khabaza, Julian Maingard, Anousha Yazdabadi, Ashu Jhamb, Mark Brooks, Dinesh Ranatunga, Davor Pavlin-Premrl, Andrew Owen, Numan Kutaiba, Michael Stewart, Behnam Shaygi, Christen Barras, Hong Kuan Kok, Hamed Asadi","doi":"10.1111/1754-9485.70152","DOIUrl":"https://doi.org/10.1111/1754-9485.70152","url":null,"abstract":"<p><strong>Introduction: </strong>This narrative review examines endovascular treatments for acute pulmonary embolism (PE), focusing on percutaneous mechanical thrombectomy (MT).</p><p><strong>Methods: </strong>PubMed (Medline) and Google Scholar were searched from January 1990 up to November 2024 (updated Feb 2026). Studies were included if they discussed PE and the use of thrombectomy devices. Full-text randomised controlled trial studies, observational studies, case series, and case reports were included. Opinion articles, letters to the editor, animal studies, and non-English studies were excluded.</p><p><strong>Results: </strong>A total of 116 articles were reviewed. Current guidelines recommend systemic thrombolysis as first-line reperfusion for high-risk PE, whereas intermediate-high-risk PE is managed with anticoagulation and monitoring, with reperfusion reserved for deterioration. MT is currently an alternative, mainly when thrombolysis is contraindicated or has failed. However, the last two decades have seen a surge in thrombectomy devices including the FlowTriever, Indigo, and AngioVac. Numerous studies, most notably the PEERLESS trial, have reported rapid haemodynamic improvement with MT, including reduced pulmonary artery pressure, low major bleeding rates, and fewer intensive care admissions [1].</p><p><strong>Conclusion: </strong>MT has shown early promise in the management of PE. Much of the current evidence derives from single-arm trials, registries, and industry-sponsored observational studies, with randomised comparative data still limited. Nonetheless, randomised evidence suggests MT may reduce clinical deterioration, intensive care use, and hospital length of stay compared with catheter-directed thrombolysis, though without a demonstrated difference in mortality, intracranial haemorrhage, or major bleeding. Further trial evidence is required before MT is recommended as first-line in PE.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative AI and Large Language Models in Medical Imaging and Radiation Oncology: Opportunity With Responsibility.","authors":"Farhannah Aly, Daniel Stahlhoven, Murray McLachlan, Kirsten Fitzpatrick, Martin Gunn","doi":"10.1111/1754-9485.70121","DOIUrl":"https://doi.org/10.1111/1754-9485.70121","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}